L1Z1 Stock Chart & Stats
€8.00
€0.70(9.59%)
At close: 4:00 PM EDT
€8.00
€0.70(9.59%)
Day’s Range― - ―
52-Week Range€5.65 - €19.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.27B
Enterprise Value€1.86K
Total Cash (Recent Filing)€118.66M
Total Debt (Recent Filing)€604.02M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Oct 29, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding153,789,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)87.63
Price to Sales (P/S)4.13
P/FCF Ratio1.14K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.33Price Target Upside66.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.28
Revenue Forecast (FY)€765.33M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationATEC's shift from multi-year negative OCF to positive trailing‑12‑month operating cash flow (~$56.5M) and slightly positive free cash flow reflects durable operating improvements and working capital discipline. Sustained positive cash generation increases flexibility to fund growth, reduce leverage, and invest in product rollout over the next several quarters.
Strong Surgeon Adoption And VolumeMaterial procedural volume growth (~20%) and substantial net new surgeon adds (~24%) indicate durable market penetration and product adoption. Higher case volumes underpin recurring implant sales, improve per-account economics, and create a longer‑term growth runway as the installed base and clinical familiarity expand across hospitals and physician practices.
Stronger Capital Structure Via New Credit FacilityThe syndicated term loan and revolving facility extends maturities to 2031, lowers borrowing costs and consolidates legacy facilities. This materially reduces near‑term refinancing risk, improves interest expense predictability and provides a scalable borrowing base to support inventory, installs, and commercial expansion over the medium term.
Bears Say
High Leverage And Negative EquityElevated total debt (~$600M+) combined with slightly negative trailing equity weakens the capital structure and reduces financial flexibility. High leverage increases interest and covenant sensitivity, limits capacity for opportunistic M&A or R&D spending, and makes the firm more vulnerable to demand or margin shocks over the next several quarters.
Sharp Recent Revenue VolatilityA nearly 48% TTM revenue decline signals meaningful volatility versus historical multi‑year growth and raises questions about demand sustainability and reporting anomalies. If persistent, such swings can strain margins, cash generation and planning, making execution on product launches and onboarding of EOS/Insight more difficult over the coming quarters.
Biologics Attachment WeaknessSubpar biologics attachment reduces revenue per case and ceded upside to larger incumbents in biologics. Given biologics' outsized contribution to procedure economics, slow commercial traction and competitive dominance create a structural headwind to improving per‑case profitability and margin expansion until attachment rates materially recover.
Alphatec Holdings News
L1Z1 FAQ
What was Alphatec Holdings’s price range in the past 12 months?
Alphatec Holdings lowest stock price was €5.65 and its highest was €19.28 in the past 12 months.
What is Alphatec Holdings’s market cap?
Alphatec Holdings’s market cap is €1.27B.
When is Alphatec Holdings’s upcoming earnings report date?
Alphatec Holdings’s upcoming earnings report date is Oct 29, 2026 which is in 83 days.
How were Alphatec Holdings’s earnings last quarter?
Alphatec Holdings released its earnings results on Aug 04, 2026. The company reported €0.061 earnings per share for the quarter, the consensus estimate of €0.061 by €0.
Is Alphatec Holdings overvalued?
According to Wall Street analysts Alphatec Holdings’s price is currently Undervalued.
Does Alphatec Holdings pay dividends?
Alphatec Holdings does not currently pay dividends.
What is Alphatec Holdings’s EPS estimate?
Alphatec Holdings’s EPS estimate is 0.08.
How many shares outstanding does Alphatec Holdings have?
Alphatec Holdings has 153,789,300 shares outstanding.
What happened to Alphatec Holdings’s price movement after its last earnings report?
Alphatec Holdings reported an EPS of €0.061 in its last earnings report, expectations of €0.061. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alphatec Holdings?
Currently, no hedge funds are holding shares in DE:L1Z1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphatec Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.33 (66.57% Upside)
€13.33 (66.57% Upside)
Blogger Sentiment
Bullish
DE:L1Z1 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $996.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.78%
Trailing 12-Months
Company Description
Alphatec Holdings
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
L1Z1 Company Deck
L1Z1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a strong quarter: double-digit revenue growth, robust surgeon adoption and case volume gains, meaningful gross margin expansion, sharply higher adjusted EBITDA and improved liquidity, plus raised profitability guidance. Headwinds are largely mix-related (international and cervical), a continued shortfall in biologics attachment rates that pressured revenue per case, early-stage EOS Insight penetration and front-loaded investments in inventory and sets that compress near-term free cash flow. Management presented concrete paths to mitigate these issues (product launches, sales discipline, EOS/Insight adoption, and balance-sheet improvements) and expressed confidence in the back half and into 2027.View all DE:L1Z1 earnings summariesL1Z1 Stock 12 Month Forecast
Average Price Target
€13.33
▲(66.57% Upside)